Investor Ideas #Potcasts: #Cannabis News and Stocks on the Move; (CSE: $AGRA.C), (CSE: $THC.C), (CSE: $MYM.C), (TSXV: $KHRN.V)
Delta, Kelowna, BC –April 9, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insights from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/04091AGRA-THC-MYM-KHRN.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another Investorideas.com “potcast” looking at cannabis news, stocks to watch as well as insights from experts and industry leaders.
Today we are looking at announcements from AgraFlora Organics International Inc., THC BioMed Intl Ltd., MYM Nutraceuticals Inc. and Khiron Life Sciences Corp..
AgraFlora Organics International Inc., (CSE: AGRA) (OTC: PUFXF) a growth oriented and diversified international cannabis company, and ICC International Cannabis Corp., have entered into an agreement whereby AgraFlora will transfer its portfolio of exotic, native Colombian cannabis genetics to ICC for international marketing and distribution purposes.
In May 2018, AgraFlora formed a wholly owned subsidiary, Pure Grow Medicinals S.A.S., to pursue cannabis cultivation and genetics opportunities in Colombia. Pure Grow has since been working in concert with a Cannabis Cup winner whose strain "Medellin Gold" has received industry accolade and has, since formation, acquired a select library of rare and exotic native cannabis seed varieties from various regions in the country.
"This partnership further equips International Cannabis with the ability to provide highly coveted Colombian cannabis flower to its global distribution network of approximately 39,000 pharmacies and retail outlets," said Eugene Beukman, Chief Executive Officer and a Director of International Cannabis. "The transfer of these native Colombian strains will also allow for the continued differentiation of the International Cannabis brand in an increasingly generic and homogenized market."
THC BioMed Intl Ltd. (CSE:THC), announced that it has received Health Canada permission to commence cannabis production in two additional strata lots at THC BioMed's flagship location in Kelowna, B.C.
The newly licensed strata lots will allow THC to begin automation of its systems allowing more efficient production, while increasing margins.
THC now has 11 strata lots licensed for production, 3 additional strata lots are being submitted for review by Health Canada, while a further 3 strata lots are currently under construction.
"While scale is essential in the development of a conglomerate, we need to properly asses the margins. We are streamlining systems to ensure quality is maintained while focusing on long term prosperity and viability," commented THC's Chief Financial Officer, Hee Jung Chun.
MYM Nutraceuticals Inc. (CSE: MYM) (OTCBB: MYMMF) announced that it has entered into a memorandum of understanding with Aqueous Sciences of Nevada, a wholly owned subsidiary of One World Ventures Inc.(OTC: OWVI), to grow 3,000 acres of hemp on Navajo Nation land located near the four corners area of Colorado, Arizona, Utah and New Mexico, USA.
MYM and Aqueous will incorporate a new company for the purpose of cultivating, extracting, and distributing hemp on 3,000 acres in New Mexico. Aqueous is the sole exclusive agent for the Navajo Nation, managing companies that wish to cultivate hemp on Navajo Nation land. MYM and Aqueous will work on an exclusive basis and will each own 50% of the new company. MYM and Aqueous plan to extend their activities to include extracting, manufacturing and distribution of hemp based products that will comply with Navajo Nation, USDA, FDA and FTC regulations and requirements.
"With the recent passing of the Farm Bill in the US, CBD-rich hemp was removed from the classified drug list, opening the door for farmers to legally grow hemp," said Howard Steinberg, CEO of MYM. "Our partnership with Aqueous is in keeping with our new strategic plan to become a global leader in the cultivation, extraction and distribution of hemp and CBD in bulk and for use in our own unique branded products."
Khiron Life Sciences Corp. (TSXV: KHRN), (OTCQB: KHRNF ), an integrated medical cannabis company with its core operations in Latin America, announced today that it has signed a definitive agreement for the acquisition of NettaGrowth International Inc., as previously announced on January 25, 2019. NettaGrowth will, at the time of the closing of the acquisition, own all of the outstanding shares of Dormul S.A., a Uruguayan company that has obtained the first licence to produce and export medical cannabis with THC for commercialization in Uruguay. As consideration for the acquisition of NettaGrowth, on closing, Khiron will issue 8,498,821 common shares to the shareholders of NettaGrowth at a deemed price of $1.61 per common share.
Alvaro Torres, CEO of Khiron, comments "This acquisition adds considerable capacity and product diversity potential to the Khiron portfolio of assets. As the first country to legalize cannabis for adult use purposes, these Uruguayan licences provide us the opportunity to address a broader demographic of consumers and export products to key regions of the world. Compared to the extract-only medical market of Colombia, the Uruguayan regulations permit the domestic and international distribution of flower. This is an excellent complement to our product focus in Colombia. I would like to thank all individuals involved in finalizing this definitive agreement and look forward to moving this transaction to close."
Uruguay was the first country to establish legislation for cannabis and Dormul has secured a medical cannabis cultivation and commercialization licence for the jurisdiction, with a cultivation capacity of up to 120 tonnes and 170,000 plants. In addition, Dormul has an application pending for an extraction licence. Upon receipt of its extraction licence, Dormul is expected to become the first company in Uruguay to be approved for medical cannabis-based CBD oils for both domestic and export purposes. With a strong commitment to research and development, Dormul has established a strategic partnership with the prestigious Institut Pasteur de Montevideo, a prestigious foundation formed between the Uruguayan and French governments focused on the research and development of cannabis product. The foundation was recently recognized by the Uruguayan Ministry of Industry for the important social and economic impact its operations are anticipated to have for the country.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Learn more about Investor ideas podcast and news publication services and costs https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
